Fecal Auto-transplantation for Enteric Microbial Rehabilitation Post 14 Day Antibiotics Therapy Against Helicobacter Pylori Infection

What this Trial Is About

Researchers are evaluating a new approach to protect the beneficial gut bacteria in people undergoing antibiotic treatment for Helicobacter pylori infection. This pilot study explores how preserving and then reintroducing a person’s own fecal microbiome could reduce side effects and prevent harm to important bacterial species during the standard 14-day antibiotic regimen used to eliminate H. pylori. The study is conducted in phases 1 and 2 to assess safety and effectiveness of this method. Participants will first provide a fresh stool sample before starting antibiotic treatment. They will then receive standard therapy to eradicate H. pylori for 14 days. After confirming eradication, participants will be randomly assigned to one of three groups: one group will receive their own microbiome transplanted back via capsules, another via enema, and a control group will receive placebo capsules. The fecal microbiome capsules are taken on two consecutive days after bowel preparation, while enemas are administered with nurse assistance and held for at least 15 minutes. During and after treatment, participants will be monitored through clinical visits where symptoms, side effects, and overall well-being will be recorded. Testing will confirm if H. pylori remains eradicated and measure restoration of gut bacterial diversity up to 18 weeks post-transplant. The study also tracks rates of re-infection and side effects over several months to understand the potential benefits and risks of this fecal auto-transplantation approach.

Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy